Collegium Announces Underwriters' Exercise Of Option To Purchase Additional Shares

CANTON, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the underwriters for its public offering of 5,000,000 shares of its common stock at $16.00 per share have exercised in full their option to purchase an additional 750,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The closing for the additional purchase of 750,000 shares is expected to take place November 29, 2016, subject to customary closing conditions. Gross proceeds from the public offering, including the underwriters' option to purchase additional shares are $92 million, excluding underwriters' discounts and commissions.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers.  William Blair & Company, L.L.C. and Needham & Company, LLC are acting as co-lead managers and Janney Montgomery Scott LLC is acting as co-manager in this offering.

The securities described above are being offered by Collegium pursuant to an effective shelf registration statement (including a base prospectus) filed with the Securities and Exchange Commission ("SEC"). Before you invest, you should read the base prospectus in the registration statement and related prospectus supplement that Collegium has filed with the SEC for more complete information about Collegium and this offering. The prospectus supplement and accompanying base prospectus are available for free by visiting EDGAR on the SEC's website located at www.sec.gov. Copies of the prospectus supplement and accompanying base prospectus, when available, may also be obtained by contacting: Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Ave, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at (800) 747-3924 or by email at prospectus@pjc.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

If you liked this article you might like

8 Stocks Spiking on Big Volume

These 5 Stocks Under $10 Could Make You a Lot of Money

Collegium Pharmaceutical (COLL) Stock Spikes on Positive FDA Committee Review